Whitehawk Therapeutics, Inc.
NASDAQ: WHWK · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-06-05
Whitehawk Therapeutics, Inc. (WHWK) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total assets | $16.66M | $18.82M | $157.91M | $184.24M | $132.42M | $70.32M | $150.83M |
| Cash & equivalents | $15.96M | $4.46M | $148.99M | $39.02M | $62.89M | $28.67M | $37.57M |
| Current assets | $16.31M | $18.68M | $151.27M | $180.03M | $124.59M | $61.29M | $149.01M |
| Total liabilities | $25.75M | $31.26M | $21.50M | $25.86M | $27.23M | $17.84M | $14.52M |
| Current liabilities | $25.62M | $30.06M | $15.27M | $18.84M | $26.39M | $17.07M | $14.52M |
| Long-term debt | — | $1.10M | — | — | — | — | — |
| Shareholder equity | $-9.09M | $-12.43M | $136.41M | $158.38M | $105.19M | $52.48M | $136.31M |
| Retained earnings | $-29.12M | $-32.59M | $-142.69M | $-203.20M | $-268.96M | $-332.65M | $-353.25M |
| Accounts receivable | $284896.00 | $14.15M | $0.00 | $1.86M | $5.49M | $5.90M | $0.00 |
| Inventory | — | — | $0.00 | $1.86M | $6.43M | $5.31M | $0.00 |
| Goodwill | — | — | — | — | — | — | — |
Frequently asked questions
How profitable is WHWK?
In its most recent fiscal year, WHWK ran a gross margin of 89.36%, an operating margin of -1,601.12%, and a net margin of -288.26%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does WHWK generate?
WHWK produced $-97.98M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is WHWK's balance sheet healthy?
WHWK holds $37.57M in cash and equivalents against — in long-term debt, on $136.31M of shareholder equity. That debt is best read against the cash flow the business throws off each year.